Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold.

scientific article published on 13 March 2016

Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1021/ACSMEDCHEMLETT.6B00060
P8608Fatcat IDrelease_4djves6elreyzfbmhjrhmafo6m
P932PMC publication ID4868099
P698PubMed publication ID27200176

P50authorAnne LeQ40504142
P2093author name stringBarbara S Slusher
Camilo Rojas
Takashi Tsukamoto
Ajit G Thomas
Marigo Stathis
Christopher Nguyen
Sarah C Zimmermann
Brad Poore
Andrew Luu
Emily F Wolf
P2860cites workFull-length human glutaminase in complex with an allosteric inhibitorQ24295587
Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolismQ27678762
Metabolism and action of amino acid analog anti-cancer agentsQ28298599
Targeting mitochondrial glutaminase activity inhibits oncogenic transformationQ34807996
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.Q35836097
Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growthQ36312149
Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors.Q36517216
Dibenzophenanthridines as inhibitors of glutaminase C and cancer cell proliferation.Q36749597
Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer.Q38039199
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancerQ39024340
Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES)Q39253539
Regulation of glutaminase activity and glutamine metabolismQ40926056
Interactions of N-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-phenyl}-2-aryl-2-yl-acetamides and 1-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-phenyl}-3-aryl-2-yl-ureas with dopamine D2 and 5-hydroxytryptamine 5HT(1A) receptors.Q51759007
P433issue5
P921main subjectallosteric inhibitorQ70361704
P304page(s)520-524
P577publication date2016-03-13
P1433published inACS Medicinal Chemistry LettersQ2819061
P1476titleAllosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold
P478volume7

Reverse relations

cites work (P2860)
Q38767151A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis
Q37247525Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer
Q51138025Conformational changes in the activation loop of mitochondrial glutaminase C: A direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activators.
Q54978523Inhibition of Glycolysis and Glutaminolysis: Emerging Drug Discovery Approach to Combat Cancer.
Q90642651Metabolic Plasticity in Chemotherapy Resistance
Q89401928Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase
Q37628958Structural basis for exploring the allosteric inhibition of human kidney type glutaminase
Q91669842Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer

Search more.